WO2008005418A3 - Assays for tak1 activity - Google Patents

Assays for tak1 activity Download PDF

Info

Publication number
WO2008005418A3
WO2008005418A3 PCT/US2007/015330 US2007015330W WO2008005418A3 WO 2008005418 A3 WO2008005418 A3 WO 2008005418A3 US 2007015330 W US2007015330 W US 2007015330W WO 2008005418 A3 WO2008005418 A3 WO 2008005418A3
Authority
WO
WIPO (PCT)
Prior art keywords
tak1
activity
measuring
ampk
methods
Prior art date
Application number
PCT/US2007/015330
Other languages
French (fr)
Other versions
WO2008005418A2 (en
Inventor
Millica Momcilovic
Marian Carlson
Seung-Pyo Hong
Original Assignee
Univ Columbia
Millica Momcilovic
Marian Carlson
Seung-Pyo Hong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia, Millica Momcilovic, Marian Carlson, Seung-Pyo Hong filed Critical Univ Columbia
Publication of WO2008005418A2 publication Critical patent/WO2008005418A2/en
Publication of WO2008005418A3 publication Critical patent/WO2008005418A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention discloses methods to identify modulators of TAK1 activity comprising measuring TAK1 activity or measuring TAK1- dependent Snf1/AMPK activity. Further disclosed are methods to measure TAK1 activity comprising measuring phosphorylation of an AMPK substrate or an increase in AMPK activity resulting from an increase in TAK1 activity. Methods to treat obesity, diabetes and diseases characterized by inflammation by administering compounds that modulate TAK1 are described also.
PCT/US2007/015330 2006-06-30 2007-06-29 Assays for tak1 activity WO2008005418A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81782306P 2006-06-30 2006-06-30
US60/817,823 2006-06-30

Publications (2)

Publication Number Publication Date
WO2008005418A2 WO2008005418A2 (en) 2008-01-10
WO2008005418A3 true WO2008005418A3 (en) 2008-10-23

Family

ID=38895174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015330 WO2008005418A2 (en) 2006-06-30 2007-06-29 Assays for tak1 activity

Country Status (1)

Country Link
WO (1) WO2008005418A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030073097A1 (en) * 2001-10-11 2003-04-17 Chen Zhijian J. TRAF6-regulated IKK activators (TRIKA1 and TRIKA2) and their use as anti-inflammatory targets
US20050026233A1 (en) * 2003-06-17 2005-02-03 Medical Research Council Methods of monitoring and modulating LKB1 activity and its downstream targets
US20050186668A1 (en) * 2000-12-21 2005-08-25 The Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
US20060040316A1 (en) * 1998-10-21 2006-02-23 Chugai Seiyaku Kabushiki Kaisha, Method for screening compounds inhibiting signal transduction through inflammatory cytokines

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060040316A1 (en) * 1998-10-21 2006-02-23 Chugai Seiyaku Kabushiki Kaisha, Method for screening compounds inhibiting signal transduction through inflammatory cytokines
US20050186668A1 (en) * 2000-12-21 2005-08-25 The Trustees Of The University Of Pennsylvania Hormonally up-regulated, neu-tumor-associated kinase
US20030073097A1 (en) * 2001-10-11 2003-04-17 Chen Zhijian J. TRAF6-regulated IKK activators (TRIKA1 and TRIKA2) and their use as anti-inflammatory targets
US20050026233A1 (en) * 2003-06-17 2005-02-03 Medical Research Council Methods of monitoring and modulating LKB1 activity and its downstream targets

Also Published As

Publication number Publication date
WO2008005418A2 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
WO2007092190A3 (en) Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity
IN2012DN00943A (en)
WO2007106236A3 (en) Pyrrolo-pyridine kinase modulators
WO2010021693A3 (en) Mif modulators
WO2008036741A3 (en) Mir-200 regulated genes and pathways as targets for therapeutic intervention
WO2012037155A3 (en) Tyrosine kinase inhibitors
WO2008013861A3 (en) Screening assay for inhibitors of trpa1 activation by a lower alkyl phenol
WO2009048072A1 (en) ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15
WO2010074588A8 (en) Pharmaceutical compounds
EA200870504A1 (en) CONNECTIONS AND COMPOSITIONS AS HEDGEHOG MODULATORS
WO2008082730A3 (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
WO2008124849A3 (en) Pyrrolo-pyridine kinase modulators
WO2005081954A3 (en) Inhibitors of protein tyrosine phosphatase 1b
WO2011140202A3 (en) Mif modulators
WO2010001169A3 (en) Chemical compounds 251
WO2008156142A1 (en) Novel malonic acid sulfonamide derivative and pharmaceutical use thereof
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010025295A3 (en) Compounds that modulate intracellular calcium
WO2008061236A3 (en) Sulfoximines as kinase inhibitors
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
WO2010031825A3 (en) Methods and compositions for the treatment of cancer
WO2007145704A3 (en) Gemcitabine combination therapy
BR112013011441A2 (en) compound, pharmaceutical composition, and use of a compound
EA200901610A1 (en) DERIVATIVES OF BIPHENILKARBOXAMIDE AS MODULATORS OF HADJHOK WAYS
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07810137

Country of ref document: EP

Kind code of ref document: A2